In order to explore the potential benefits (and risks) associated with HCQ, WHO included it in the global Solidarity trials testing different therapies to find an ideal way to treat and prevent COVID-19.
But, as the tests progressed, The Lancet published a study suggesting that the drug has no benefit in treating COVID-19 and might even increase the risk of dying for some.
On June 3, a little over a week after the trials were suspended, WHO chief Tedros Adhanom Ghebreyesus clarified that the mortality data available on the drug is safe, and "there are no reasons to modify the trial protocol."
He said, "The executive group [of the trial] received this recommendation and [has] endorsed [the] continuation of all arms of the Solidarity Trial, including Hydroxychloroquine."
With this clearance, the WHO trial exploring Hydroxychloroquine is expected to resume soon.
"The executive group will communicate with the principal investigators in the trial about resuming the Hydroxychloroquine arm of the trial," the WHO chief said, per AFP. "The data safety and monitoring committee will continue to closely monitor the safety of all therapeutics being tested in the Solidarity Trial."
So far, nearly 64 lakh have been infected by COVID-19
The HCQ clearance from the WHO chief comes as the scientific community races to find a treatment for COVID-19 and stop the ongoing pandemic. The disease started spreading in late December and has killed nearly 3.86 lakh people worldwide, with nearly 64 lakh being infected.